SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival (NCT04415060)
SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study
🩺 Plain-English Summary (8th-Grade Level)
Patients suffering lung failure, possibly from COVID-19 or hypoxic lung failure, will need life-saving support from a breathing machine. Any patient needing this support requires drugs to keep them sleepy, or "sedated" to be comfortable on this machine. Sedation is made possible by using drugs given through a vein. Unfortunately, these drugs are in short supply worldwide due to the high number of COVID-19 patients needing these machines. Another way to provide sleep is by using gases that are breathed in. These are used every day in operating rooms to perform surgery. These gases, also called "inhaled agents" can also be used in intensive care units and may have several important benefits for patients and the hospital. Research shows they may reduce swelling in the lung and increase oxygen levels, which allows patients to recover faster and reduce the time spent on a breathing machine. In turn, this allows the breathing machine to be used again for the next sick patient. These drugs may also increase the number of patients who live through their illness. Inhaled agents are widely available and their use could dramatically lesson the pressure on limited drug supplies. This research is a study being carried out in a number of hospitals that will compare how well patients recover from these illnesses depending on which type of sedation drug they receive. The plan is to evaluate the number who survive, their time spent on a breathing machine and time in the hospital. This study may show immediate benefits and may provide a cost effective and practical solution to the current challenges caring for patients and the hospital space, equipment and drugs to the greatest benefit. Furthermore, the study will be investigating inflammatory profile and neuro-cognitive profiles in ventilated patients. Finally, this trial will be a team of experts in sedation drugs who care for patients with proven or suspected COVID-19 who need lifesaving treatments.
Who can join: Review the eligibility criteria below.
Location: University of Alberta Hospital — Edmonton, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of Alberta Hospital — Edmonton, Alberta
- Grey Nuns Community Hospital — Edmonton, Alberta
- London Health Sciences Centre - University Hospital — London, Ontario
- London Health Sciences Centre - Victoria Hospital — London, Ontario
- The Ottawa Hospital — Ottawa, Ontario
- Sunnybrook Health Sciences Centre — Toronto, Ontario
- University Health Network - Toronto General Hospital — Toronto, Ontario
- University Health Network - Toronto Western Hopsital — Toronto, Ontario
- Centre Hospitalier de l'Université de Montréal — Montreal, Quebec
- McGill University Health Centre - Royal Victoria Hospital — Montreal, Quebec
- Hôpital Sacré-Coeur de Montréal — Montreal, Quebec
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ) — Québec, Quebec
- Universite de Sherbrooke — Sherbrooke, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Covid19
- Pediatric COVID Outcomes Study (PECOS) — Washington D.C., District of Columbia
- COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation — Rochester, Minnesota
- The Canadian COVID-19 Prospective Cohort Study — Calgary, Alberta
- Post Acute Sequelae of COVID-19 — Nashville, Tennessee
- Lung Structure-Function In Survivors of Mild and Severe COVID-19 Infection — Hamilton, Ontario
Explore by condition: All Covid19 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.